[
  {
    "ts": null,
    "headline": "Medtronic plc (MDT): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
    "summary": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years […]",
    "url": "https://finnhub.io/api/news?id=d2b8c4502a624458a507d9f26827f9d213aea2dbae67575ce8222c92e11d2cf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743376845,
      "headline": "Medtronic plc (MDT): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
      "id": 133622757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years […]",
      "url": "https://finnhub.io/api/news?id=d2b8c4502a624458a507d9f26827f9d213aea2dbae67575ce8222c92e11d2cf1"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients",
    "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology's",
    "url": "https://finnhub.io/api/news?id=2ce4f07c7aa18e9bdbf7701ca65a4cc048092c952b062ee6bd848f03e3f16f40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743346800,
      "headline": "Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients",
      "id": 133622758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology's",
      "url": "https://finnhub.io/api/news?id=2ce4f07c7aa18e9bdbf7701ca65a4cc048092c952b062ee6bd848f03e3f16f40"
    }
  }
]